Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20–59 years: NHANES 2009–2018
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309345 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Harun Mazumder und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Statistical Research and Training, University of Dhaka, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Hepatitis C, Nutrition Surveys. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The people who inject drugs (PWID) are attributed to high-risk groups for transmission of the Hepatitis C virus (HCV). This study assessed the prevalence and associated factors of current HCV infection (CHI) among U.S. general population and PWID of ages between 20 and 59 years old.
Methods
This study utilized cross-sectional data from the 2009–2018 National Health and Nutrition Examination Survey, conducting separate analyses for the U.S. general population, including PWID and non-PWID, as well as specific analyses focusing solely on PWID. The analytical methods included the estimation of CHI prevalence, Rao-Scott chi-square test to compare CHI-positive and CHI-negative groups, and univariate and multivariable logistic regressions models to evaluate the associated risk factors of CHI.
Results
The prevalence of CHI among general population and PWID were 1% and 19%, respectively. Compared to non-PWID, the odds of CHI were significantly higher among PWID (OR = 32.6, 95% CI = 17.7–60.3) in general population. Among PWID, male vs. female (OR = 2.6, 95% CI = 1.1–5.9), adults aged 40–59 vs. 20–39 years old (OR = 2.9, 95% CI = 1.2–7.3), Non-Hispanic Black vs. White (OR = 4.6, 95% CI = 1.5–13.6), with high school diploma or less educational attainment vs. above college degree (OR = 3.5, 95% CI = 1.4–9.2) showed higher odds of having CHI.
Conclusion
The prevalence of CHI was found to be higher among PWID especially those who were male, aged 40–59 years old, Non-Hispanic Black, and had lower educational attainment. Targeted intervention such as screening and awareness program among PWID population is recommended to reduce the burden of new HCV infections in the U.S.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Statistical Research and Training, University of Dhaka, Dhaka, Bangladesh.
- School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, United States of America.
- School of Medicine, Washington University, St. Louis, MO, United States of America.
- Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
- Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.
- Department of Zoology, National University, Gazipur, Bangladesh.
ORCID-Profile: Md Faruk Hossain, Pratibha Shrestha, Sultan Mahmud
Zitieren
APA
Mazumder, H., Hossain, M. F., Shrestha, P., Mahmud, S., Husain, M., & Ahmed, R. (2024). Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20–59 years: NHANES 2009–2018. PLOS ONE. https://doi.org/10.1371/journal.pone.0309345
Vancouver
Mazumder H, Hossain MF, Shrestha P, Mahmud S, Husain M, Ahmed R. Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20–59 years: NHANES 2009–2018. PLOS ONE. 2024. doi:10.1371/journal.pone.0309345
BibTeX
@article{Mazumder2024,
author = {Mazumder, Harun and Hossain, Md Faruk and Shrestha, Pratibha and Mahmud, Sultan and Husain, Maidul and Ahmed, Rebeka},
title = {Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20–59 years: NHANES 2009–2018},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309345}
}
EUVIMED